Carisma Therapeutics
CARM
CARM was delisted on the 10th of October, 2025.
46 hedge funds and large institutions have $18.8M invested in Carisma Therapeutics in 2019 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 14 increasing their positions, 7 reducing their positions, and 6 closing their positions.
693% more call options, than puts
Call options by funds: $1.74M | Put options by funds: $219K
150% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 6
100% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 7
24% more funds holding
Funds holding: 37 → 46 (+9)
0.29% less ownership
Funds ownership: 1.15% → 0.86% (-0.29%)
31% less capital invested
Capital invested by funds: $27.3M → $18.8M (-$8.59M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EP
Eversept Partners
New York
|
+$1.49M |
| 2 |
BlackRock
New York
|
+$715K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$436K |
| 4 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$289K |
| 5 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$289K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CH
CVI Holdings
Wilmington,
Delaware
|
-$5.54M |
| 2 |
KCM
Kingdon Capital Management
New York
|
-$4.95M |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
-$167K |
| 4 |
Wells Fargo
San Francisco,
California
|
-$113K |
| 5 |
MTIM
Marathon Trading Investment Management
Radnor,
Pennsylvania
|
-$42.4K |
CARM Hedge Fund Activity: Q4 2019 in Review
46 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Carisma Therapeutics (CARM) for Q4 2019, worth a combined $18.8M — down 31% from $27.3M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new CARM positions and 6 closed out — a net gain of 9 holders — while 14 added to existing stakes and 7 trimmed.
The largest buyer was Eversept Partners, opening a new position worth an estimated $1.49M. The largest seller was CVI Holdings, exiting entirely with an estimated $5.54M sold.
- 46 institutional investors held Carisma Therapeutics (CARM) as of Q4 2019, up from 37 in Q3 2019.
- Funds reported $18.8M of Carisma Therapeutics stock for Q4 2019, down 31% quarter-over-quarter.
- 15 funds opened new Carisma Therapeutics positions in Q4 2019 and 6 closed out, a net change of +9 holders.
- The largest Carisma Therapeutics buyer in Q4 2019 was Eversept Partners, an estimated $1.49M added.
- The largest Carisma Therapeutics seller in Q4 2019 was CVI Holdings, an estimated $5.54M sold.
Based on aggregated 13F filings for Q4 2019.